Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a virtual presentation at the BofA Securities 2020 Health Care Conference at 3:00 p.m. ET on Wednesday, May 13, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
WALTHAM, Mass., Jan. 08, 2020 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
- Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track.
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro.
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Marc Schegerin, M.D., as chief financial officer and chief operating officer. Dr. Schegerin was most recently chief financial officer of ArQule and joins Morphic with extensive experience in the biotechnology space spanning clinical and business development, strategy, finance and operations. “Marc is a veteran industry professional with an accomplished and diverse background in healthcare investment banking, drug development and medicine,” said Praveen Tipirneni, president and chief executive officer of Morphic Therapeutic.
WALTHAM, Mass., Aug. 30, 2019 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
WALTHAM, Mass., Feb. 28, 2020 -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the.
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...
WALTHAM, Mass., Nov. 18, 2019 -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by.
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that the Morphic executive team is scheduled to make a presentation at the Jefferies Virtual Healthcare Conference at 2:30 p.m. ET on Wednesday, June 3, 2020. Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.
WALTHAM, Mass., Feb. 27, 2020 -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of.
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as.
Morphic Therapeutic (MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced the appointment of Peter G. Linde, M.D., as chief medical officer. Dr. Linde was previously vice president of medical research at Acceleron Pharma, Inc., where he was responsible for the design and execution of clinical trials with positive outcomes in both pulmonary and hematologic diseases. Dr. Linde will oversee the development of Morphic’s small molecule integrin inhibitors as the company advances its oral integrin inhibitors toward clinical trials.